title: Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
abstract: The effect of achieving a sustained virological response (SVR) following interferon-alpha (IFNalpha) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNalpha treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNalpha monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNalpha discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of all outcomes were assessed by Cox regression analysis. Of 920 patients, 124 (13.5%) were classified as achieving a SVR. During a mean follow-up of 96.1 months (range: 6-167) the incidence rates per 100 person-years of liver-related complications, HCC and liver-related death were 0, 0.66, and 0.19 among SVR and 1.88, 2.10, and 1.44 among non-SVR (P<0.001 by log-rank test). Multivariate analyses found that non-SVR was associated with a higher risk of liver-related complications (hazard ratio, HR, not applicable), HCC (HR 2.59; 95% CI 1.13-5.97) and liver-related mortality (HR 6.97; 95% CI 1.71-28.42) as compared to SVR.
  
  
  CONCLUSIONS
  Thus, in patients with HCV-related, histologically proven cirrhosis, achievement of a SVR after IFNalpha therapy was associated with a reduction of liver-related mortality lowering both the risk of complications and HCC development. Irrespective of SVR achievement, all patients should continue surveillance because the risk of occurrence of HCC was not entirely avoided.
authors.affiliation: Liver Unit, Department of Medicine, AO Fatebenefratelli e Oftalmico, Milan, Italy.
authors.forename: Savino
authors.initials: S
authors.lastname: Bruno
authors.forename: Tommaso
authors.initials: T
authors.lastname: Stroffolini
authors.forename: Massimo
authors.initials: M
authors.lastname: Colombo
authors.forename: Simona
authors.initials: S
authors.lastname: Bollani
authors.forename: Luisa
authors.initials: L
authors.lastname: Benvegnù
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mazzella
authors.forename: Antonio
authors.initials: A
authors.lastname: Ascione
authors.forename: Teresa
authors.initials: T
authors.lastname: Santantonio
authors.forename: Felice
authors.initials: F
authors.lastname: Piccinino
authors.forename: Pietro
authors.initials: P
authors.lastname: Andreone
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mangia
authors.forename: Giovanni B
authors.initials: GB
authors.lastname: Gaeta
authors.forename: Marcello
authors.initials: M
authors.lastname: Persico
authors.forename: Stefano
authors.initials: S
authors.lastname: Fagiuoli
authors.forename: Piero L
authors.initials: PL
authors.lastname: Almasio
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral